Atopic Dermatitis

Phase 3 trial data from the INTEGUMENT-1 study yielded positive results for roflumilast cream on atopic dermatitis patients ages 6 and up.

A recent discussion with Dr. Brown on the use of tapinarof, approved for adult plaque psoriasis, in patients with atopic dermatitis.

An analysis of serum dupilumab treatment for atopic dermatitis patients suggests a lack of association between either response or adverse effects.

A discussion with the moderator of the Global Parents for Eczema Research symposium regarding climate change and the effects of fire, drought, airborne pollution on atopic dermatitis.

A discussion with Dr. Boos on the topic of climate change and airborne pollution exposure leading to or exacerbating atopic dermatitis.

A recent research letter highlighted a case observed in Japan in which a patient with alopecia totalis, and an associated case of atopic dermatitis, was treated effectively with baricitinib, a JAK inhibitor.

Recent phase 3 trial data suggests the efficacy across multiple endpoints of roflumilast foam as a treatment for seborrheic dermatitis.

New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.

Dermatologists and primary care physicians believe there is a significant unmet need for treatments for patients with mild or moderate atopic dermatitis.

When compared to an intervention system guided by a therapist, a newly-designed self care system for atopic dermatitis patients may be as helpful.

The Recap of Atopic Eczema (RECAP) and Atopic Dermatitis Control Tool (ADCT) were recommended to measure eczema control.

A recent study confirmed the safety of tralokinumab with regard to COVID-19 and related vaccinations.

Researchers evaluated the use of IVIG for patients with the rare autoimmune disorder dermatomyositis.

A recent cohort study of 20 emergency departments assessed allergic contact dermatitis cases.

A discussion with Dr. Lal on the successful trials and recent approval of dupilumab as a treatment for skin inflammation.

Alexa Hetzel, MA, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, and Matthew Brunner, PA, share practice pearls and clinical management tips for the care of pediatric patients with atopic dermatitis.

Experts in dermatology hypothesize about the next round of treatment disruptions and their hopes for the future of atopic dermatitis management.

Alexa Hetzel, MA, PA-C, and Lakshi Aldredge, MSN, ANP-BC, DCNP, provide insight into emerging therapies and ongoing investigations in the management of pediatric atopic dermatitis.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

Experts in dermatology comment on the impact of treatment response time on pediatric atopic dermatitis burden.

Alexa Hetzel, MA, PA-C; Matthew Brunner, PA; and Lakshi Aldredge, MSN, ANP-BC, DCNP, share their real-world utilization experiences with dupilumab in pediatric patients with atopic dermatitis.

Experts in dermatology stress the importance of patient education in atopic dermatitis management and discuss their approaches to keeping patients up-to date.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, provide insight into emerging therapies and future directions in the management of pediatric atopic dermatitis.

A discussion on research into allergic contact dermatitis and its connection to allergens in skincare products.

Lakshi Aldredge, MSN, ANP-BC, DCNP, reviews the evolution of the treatment landscape for pediatric patients with atopic dermatitis; highlighting recent advances.